Abstract Cyclin-dependent kinases (CDKs) play a central role in cell cycle control, apoptosis, transcription and neuronal functions. They are important targets for the design of drugs with antimitotic or antineurodegenerative effects. CDK4 and CDK6 form a subfamily among the CDKs in mammalian cells, as defined by sequence similarities. Compared to CDK2 and CDK5, structural information on CDK4 and CDK6 is sparse. We describe here the complex structure of human CDK6 in complex with a viral cyclin and a flavonol inhibitor, fisetin. Fisetin binds to the active form of CDK6, forming hydrogen bonds with the side chains of residues in the binding pocket that undergo large conformational changes during CDK activation by cyclin binding. The 4-keto group and the 3-hydroxyl group of fisetin are hydrogen bonded with the backbone in the hinge region between the N-terminal and C-terminal kinase domain, as has been observed for many CDK inhibitors. However, CDK2 and HCK kinase in complex with other flavonol inhibitors such as quercetine and flavopiridol showed a different binding mode with the inhibitor rotated by about 180°. The structural information of the CDK6-fisetin complex is correlated with the binding affinities of different flavonol inhibitors for CDK6. This complex structure is the first description of an inhibitor complex with a kinase from the CDK4/6 subfamily and can provide a basis for selecting and designing inhibitor compounds with higher affinities and specificities. Values in parentheses refer to the highest resolution shell. 1 R cryst = ∑h||Fobs(h)|-|Fc(h)||/∑h|Fobs(h)| for all data, R free was calculated from 7.5% of structure factor amplitudes that were excluded from refinement; 2 Overall/outer shell; 3 R sym = ∑hkl∑i |I-<I>|/∑hkl∑I; 4 Most favored region in Ramachandran plot as defined in PROCHECK.
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Overall Structure of the Complex
• • Fisetin (3,7,3',4'-Tetrahydroxyflavone) is a relatively small flavonol inhibitor with a hydroxyl-group in the 3 position of the benzopyran ring. This distinguishes it from several other flavonol inhibitors whose inhibitory activity on CDK6-Vcyclin was determined in this study as well ( • • Additional substituent in the 2'-phenyl ring may create a inhibitor with higher affinity to CDK6. • • Exploring substitutions in the 6/7 -benzopyran ring may lead to a more specific inhibitor for CDK6. • • It's better to increase the structural information on CDK6-inhibitor complexes, to help to design more specific inhibitory compounds. 
